New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
04:55 EDTCGIX, CGIX, CGIX, HART, HART, HART, NURO, NURO, NURO, CANF, CANF, CANF, AMBS, AMBS, AMBS, AGEN, AGEN, AGEN, AVXL, AVXL, AVXL, SYN, SYN, SYN, CEMI, CEMI, CEMI, SRNE, SRNE, SRNE, OXBT, OXBT, OXBTOneMedPlace to hold a forum
7th Annual OneMedForum SF 2014 is being held in San Francisco on January 13-15.
News For CGIX;SRNE;CEMI;SYN;AVXL;AGEN;AMBS;CANF;NURO;HART;OXBT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
07:45 EDTCGIXCancer Genetics awarded multimillion dollar clinical trial
Cancer Genetics announced that it has been awarded a multimillion dollar, clinical trial in hematological cancers by a leading biotech company the trial is the largest in the company's history of providing clinical trial and genomic services to global biopharma companies. As part of the agreement, CGI will perform all testing, and provide genomic information and monitoring for CLL patients enrolled in multi-arm, randomized, multicenter, global trials. The CLL trials are expected to contribute up to $6.2M in revenue over several years as patients are selected, treated, and monitored using pathway-specific, targeted therapies, and combination therapies.
June 29, 2015
18:28 EDTSRNESorrento Therapeutics CFO Mark Durand retires
Subscribe for More Information
09:18 EDTSYNOn The Fly: Pre-market Movers
Subscribe for More Information
07:36 EDTAGENAgenus coverage assumed with a Buy at H.C. Wainwright
Subscribe for More Information
07:04 EDTCANFCan-Fite BioPharma announces further progress in preclinical program of CF602
Subscribe for More Information
07:00 EDTSYNSynthetic Biologics initiates SYN-010 Phase 2 clinical trial
Synthetic Biologics reported the initiation of a Phase 2 clinical trial of its proprietary SYN-010 for the treatment of irritable bowel syndrome with constipation, or IBS-C. This is a placebo-controlled study to evaluate the ability of two dose strengths of SYN-010 to reduce the production of methane in breath methane-positive patients with IBS-C. Breath methane is strongly associated with constipation in IBS-C and higher methane levels are proportional to constipation severity. This Phase 2, randomized, double-blind, parallel-group, placebo-controlled, multi-dose study is expected to be conducted at multiple centers in the United States. The primary objective of this study is to evaluate the change from baseline in breath methane, as determined by a lactulose breath test, in methane-positive patients with IBS-C after seven days of treatment with one of two formulations of SYN-010 compared with placebo. Approximately 60 patients will be enrolled and randomly assigned in a 1:1:1 ratio to one of three groups, including two different SYN-010 dose groups and a placebo group. Patients are scheduled to receive single oral doses of SYN-010 each day for 28 days.
June 25, 2015
08:03 EDTHARTHarvard Apparatus names James McGorry as CEO, effective July 6
Harvard Apparatus Regenerative Technology announced the appointment of James McGorry, MBA, as CEO, effective July 6. McGorry has more than 25 years of experience as a life science business leader in biologics, personalized medicine and medical devices, including multiple product launches. He also has been a member of the HART Board of Directors since February 2013. HART plans to provide a corporate update on its second quarter financial call in August following a business review by McGorry and the management team.
June 24, 2015
09:13 EDTSRNESorrento Therapeutics subsidiary receives MUMS drug designation in dogs
Subscribe for More Information
June 23, 2015
13:00 EDTAGENTheStreet's Feuerstein pans bullish Agenus initiation
Subscribe for More Information
07:36 EDTAGENJMP Securities to hold a conference
Subscribe for More Information
June 19, 2015
07:23 EDTAMBSBrewer Capital Management to hold a conference
Subscribe for More Information
07:01 EDTCANFCan-Fite subsidiary OphthaliX agrees to acqure Improved Vision Systems
Subscribe for More Information
June 17, 2015
07:01 EDTSYN, AGENAgenus names C. Evan Ballantyne as CFO, effective immediately
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use